Oklahoma SB 771 was introduced at the end of January and referred to the Senate Health and Human Services Committee. The bill would prohibit certain direct-to-consumer advertising by pharmaceutical companies. “Direct-to-consumer pharmaceutical advertising” includes “any promotional communication targeting consumers including, but not limited to television, radio, print media, digital platforms, social media, and print and […]
Read more
Sept. 9, 2019 – In its first Warning Letter of 2019, the FDA’s Office of Prescription Drug Promotion (OPDP), continues to call out the omission of risk information cited in previous Untitled Letters this year, stating that Metuchen Pharmaceuticals LLC’s direct-to-consumer (DTC) print ad and display banners for its erectile dysfunction (ED) drug include claims […]
Read more
Aug. 20, 2018 – The FDA continues to consider whether the amount and location of risk disclosure information currently appearing in direct-to-consumer (DTC) print ads – both in the brief summary and the “important safety information” (ISI) section – has the potential to “overwarn” consumers. In an FDA notice in the Federal Register last week, […]
Read more